2025 Q4 -tulosraportti
39 päivää sitten
‧53 min
1,60 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 49 | - | - | ||
| 60 | - | - | ||
| 38 | - | - | ||
| 100 | - | - | ||
| 3 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 139 | 4 139 | 0 | 4 139 |
| Anonyymi | 68 030 | 68 030 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 139 | 4 139 | 0 | 4 139 |
| Anonyymi | 68 030 | 68 030 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 16.3. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenALK has fallen this year after 3 years of good increases. It has also risen more than earnings as I see it, but it is certainly a good stock and a good company. However, I'm not sure it will provide big surprises for the portfolio in 2026, so it is currently on my candidate bench for replacement for a period. It is very highly priced in relation to its growth, which is quite certainly fine, but there also needs to be realism. I had actually decided that it should remain in my portfolio for a long time, but it is also expensive to tie up capital for a very limited probability of greater growth in the short term. However, I will keep it until there is hopefully a clarification of the situation in the Middle East. There is a possibility that ALK in the meantime will return to 220 in price and then I will say goodbye for this time.
·41 min sittenYes, it is relatively expensive measured by p/e. It has historically been so. It is probably also the price that has caused it to fall this year, because they deliver what they promise. They invest up to 1 billion Kroner in pipeline and research. It could be that EBIT margins are shifting. I still believe we will get an EBIT margin around 26 pct when the year is over, as guidance is cautious. They are in the right markets with everything that is happening outside Europe. I will not sell mine at current levels.
·23.3. · MuokattuOnly profit and buy recommendations. C 25 is rising, but alk is standing still
·25.3.When will this be picked up?·25.3.Really good time to supplement a bit in alk. They are growing well. Few competitors. Higher p/e so somewhat affected by interest rate hikes. They have never been stronger. Started paying dividends for the first time in a very long time. Primary sales in Europe. Exciting in other parts of the world, but in the short term, good with Europe as the primary market. Now it is cheaper but nothing has changed.
·17.3.From Børsen on 21.02.2026 a page about/with Peter Halling about the future: Peanuts in focus he denies that it is an ud tryk for, that it is written in the stars how the jordnød tablet will perform, but he is eagerly awaiting trial data. according to analysts, success with a solution for jord nøddeallergikere could secure an annual peak sales potential of 1 billion dollars – roughly the same as ALK's revenue in 2025. “it is important for our future growth, but it is not crucial for the company,” says Peter Halling about the pill, which could potentially be launched in 2030. I remember Carsten Hellmann stated, when he was CEO, that the risk in phase 1, 2 and 3 was very small, as they could do the same with airways as with food. Is the aforementioned future plan included in your considerations?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
39 päivää sitten
‧53 min
1,60 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenALK has fallen this year after 3 years of good increases. It has also risen more than earnings as I see it, but it is certainly a good stock and a good company. However, I'm not sure it will provide big surprises for the portfolio in 2026, so it is currently on my candidate bench for replacement for a period. It is very highly priced in relation to its growth, which is quite certainly fine, but there also needs to be realism. I had actually decided that it should remain in my portfolio for a long time, but it is also expensive to tie up capital for a very limited probability of greater growth in the short term. However, I will keep it until there is hopefully a clarification of the situation in the Middle East. There is a possibility that ALK in the meantime will return to 220 in price and then I will say goodbye for this time.·41 min sittenYes, it is relatively expensive measured by p/e. It has historically been so. It is probably also the price that has caused it to fall this year, because they deliver what they promise. They invest up to 1 billion Kroner in pipeline and research. It could be that EBIT margins are shifting. I still believe we will get an EBIT margin around 26 pct when the year is over, as guidance is cautious. They are in the right markets with everything that is happening outside Europe. I will not sell mine at current levels.
- ·23.3. · MuokattuOnly profit and buy recommendations. C 25 is rising, but alk is standing still·25.3.When will this be picked up?·25.3.Really good time to supplement a bit in alk. They are growing well. Few competitors. Higher p/e so somewhat affected by interest rate hikes. They have never been stronger. Started paying dividends for the first time in a very long time. Primary sales in Europe. Exciting in other parts of the world, but in the short term, good with Europe as the primary market. Now it is cheaper but nothing has changed.
- ·17.3.From Børsen on 21.02.2026 a page about/with Peter Halling about the future: Peanuts in focus he denies that it is an ud tryk for, that it is written in the stars how the jordnød tablet will perform, but he is eagerly awaiting trial data. according to analysts, success with a solution for jord nøddeallergikere could secure an annual peak sales potential of 1 billion dollars – roughly the same as ALK's revenue in 2025. “it is important for our future growth, but it is not crucial for the company,” says Peter Halling about the pill, which could potentially be launched in 2030. I remember Carsten Hellmann stated, when he was CEO, that the risk in phase 1, 2 and 3 was very small, as they could do the same with airways as with food. Is the aforementioned future plan included in your considerations?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 49 | - | - | ||
| 60 | - | - | ||
| 38 | - | - | ||
| 100 | - | - | ||
| 3 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 139 | 4 139 | 0 | 4 139 |
| Anonyymi | 68 030 | 68 030 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 139 | 4 139 | 0 | 4 139 |
| Anonyymi | 68 030 | 68 030 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 16.3. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
2025 Q4 -tulosraportti
39 päivää sitten
‧53 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 5.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 16.3. | ||
2025 Q4 -tulosraportti 20.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 |
1,60 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenALK has fallen this year after 3 years of good increases. It has also risen more than earnings as I see it, but it is certainly a good stock and a good company. However, I'm not sure it will provide big surprises for the portfolio in 2026, so it is currently on my candidate bench for replacement for a period. It is very highly priced in relation to its growth, which is quite certainly fine, but there also needs to be realism. I had actually decided that it should remain in my portfolio for a long time, but it is also expensive to tie up capital for a very limited probability of greater growth in the short term. However, I will keep it until there is hopefully a clarification of the situation in the Middle East. There is a possibility that ALK in the meantime will return to 220 in price and then I will say goodbye for this time.·41 min sittenYes, it is relatively expensive measured by p/e. It has historically been so. It is probably also the price that has caused it to fall this year, because they deliver what they promise. They invest up to 1 billion Kroner in pipeline and research. It could be that EBIT margins are shifting. I still believe we will get an EBIT margin around 26 pct when the year is over, as guidance is cautious. They are in the right markets with everything that is happening outside Europe. I will not sell mine at current levels.
- ·23.3. · MuokattuOnly profit and buy recommendations. C 25 is rising, but alk is standing still·25.3.When will this be picked up?·25.3.Really good time to supplement a bit in alk. They are growing well. Few competitors. Higher p/e so somewhat affected by interest rate hikes. They have never been stronger. Started paying dividends for the first time in a very long time. Primary sales in Europe. Exciting in other parts of the world, but in the short term, good with Europe as the primary market. Now it is cheaper but nothing has changed.
- ·17.3.From Børsen on 21.02.2026 a page about/with Peter Halling about the future: Peanuts in focus he denies that it is an ud tryk for, that it is written in the stars how the jordnød tablet will perform, but he is eagerly awaiting trial data. according to analysts, success with a solution for jord nøddeallergikere could secure an annual peak sales potential of 1 billion dollars – roughly the same as ALK's revenue in 2025. “it is important for our future growth, but it is not crucial for the company,” says Peter Halling about the pill, which could potentially be launched in 2030. I remember Carsten Hellmann stated, when he was CEO, that the risk in phase 1, 2 and 3 was very small, as they could do the same with airways as with food. Is the aforementioned future plan included in your considerations?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 49 | - | - | ||
| 60 | - | - | ||
| 38 | - | - | ||
| 100 | - | - | ||
| 3 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 139 | 4 139 | 0 | 4 139 |
| Anonyymi | 68 030 | 68 030 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Nordea Bank Abp | 4 139 | 4 139 | 0 | 4 139 |
| Anonyymi | 68 030 | 68 030 | 0 | 0 |